ChemicalBook >> CAS DataBase List >>Cetuximab

Cetuximab

CAS No.
205923-56-4
Chemical Name:
Cetuximab
Synonyms
EGFR antibody;IMC 225;Hsdb 7454;CETUXIMAB;CetuxiMab(C225);Unii-pqx0D8J21j;CETUXIMAB USP/EP/BP;Cetuximab (anti-EGFR);6-Diaminoheptanedioic acid;Cetuximab - Buffer solution
CBNumber:
CB82448505
Molecular Formula:
C107H179N35O36S7
Molecular Weight:
2756.23406
MDL Number:
MFCD06407972
MOL File:
205923-56-4.mol
Last updated:2023-05-21 10:59:17

Cetuximab Properties

storage temp. Store at 4°C, do not freeze
NCI Dictionary of Cancer Terms cetuximab
FDA UNII PQX0D8J21J
NCI Drug Dictionary cetuximab
ATC code L01XC06

Pharmacokinetic data

Excreted unchanged in urine Minimal
Volume of distribution 1.5-6.2 L/m2(L/kg)
Biological half-life 70-100 / Unchanged

Cetuximab price

Manufacturer Product number Product description CAS number Packaging Price Updated Buy
Usbiological 384860 Cetuximab 205923-56-4 96Tests $1114 2021-12-16 Buy
Biosynth Carbosynth FC64978 Cetuximab - Buffer solution 205923-56-4 25mg $1500 2021-12-16 Buy
ChemScene CS-7491 Cetuximab 99.70% 205923-56-4 25mg $2550 2021-12-16 Buy
ChemScene CS-7491 Cetuximab 99.70% 205923-56-4 50mg $4080 2021-12-16 Buy
Biorbyt Ltd orb86357 EGFR antibody Immunoaffinity purified 205923-56-4 50μg $725.9 2021-12-16 Buy
Product number Packaging Price Buy
384860 96Tests $1114 Buy
FC64978 25mg $1500 Buy
CS-7491 25mg $2550 Buy
CS-7491 50mg $4080 Buy
orb86357 50μg $725.9 Buy

Cetuximab Chemical Properties,Uses,Production

Description

Cetuximab, a human/mouse chimeric monoclonal antibody that blocks the EGFR, was launched for use in combination with irinotecan in the treatment of patients with colorectal cancer who no longer respond to standard chemotherapy treatment with irinotecan. Cetuximab is obtained by chimerization of M225, a murine anti-EGFR antibody; specifically heavy and light chains of the murine antibody are cloned and adapted for expression with constant regions of the human kappa light chain and human gamma1 heavy chain. It is produced by mammalian (suspension) cells in serum-free medium, purified by protein A affinity chromatography, ion-exchange chromatography, and gel filtration. Cetuximab binds specifically to EGFR on both normal and tumor cells. Overexpression of the human EGFR is detected in many cancers, including those of the colon and rectum. The binding of cetuximab to EGFR prevents growth factors from binding to the receptor, thereby inhibiting cell growth and inducing apoptosis. The therapeutic regimen of cetuximab consists of an initial loading dose of 400 mg/m2 administered as a 120-min IV infusion, followed by weekly maintenance dose of 250 mg/m2 infused over 60 min. The steady-state plasma concentrations of cetuximab are reached by the third weekly infusion and the mean elimination half-life is 114 h. Cetuximab is eliminated by binding to EGFRs in various tissues, followed by internalization of the antibody- EGFR complex. Systemic clearance of the antibody is saturated at higher doses, and this appears to correlate with saturation of EGFR binding. In a multicenter clinical trial in more than 300 patients with advanced metastatic colorectal cancer, combination therapy with cetuximab and irinotecan produced response in more than half of the patients, shrinking tumors in 23% and stopping tumor growth in an additional 33% of the patients. The most common adverse reactions associated with cetuximab were acneform rash, asthenia/malaise, fever, nausea, abdominal pain, constipation and vomiting. Serious adverse events such as infusion reaction, fever, sepsis, kidney failure, dehydration and diarrhea were experienced by <10% of the patients.

Originator

ImClone (US)

Uses

Treatment of EGF receptor-expressing cancers (monoclonal antibod.

brand name

Erbitux

Mechanism of action

Cetuximab, a monoclonal antibody, binds to the extracellular domain of the EGFR, which is overexpressed in many human cancers, including head, neck, and colorectal types. This process prevents the EGFR from binding with its endogenous ligand, blocking the receptor-dependent transduction pathway and providing many antitumor effects involving cell-cycle arrest, induction of apoptosis, inhibition of angiogenesis, inhibition of metastasis, internalization, and downregulation of the EGFR, and enhancement of the sensitivity to radiochemotherapy[1].
Cetuximab

Clinical Use

Monoclonal antibody:
Treatment of EGFR-expressing metastatic colorectal cancer in combination with irinotecan after failure of irinotecan-including cytotoxic therapy

Treatment of head and neck cancer

Toxicology

The majority of skin toxicities were mild to moderate, symptomatic treatments were effective in controlling them. The skin discomfort caused by cetuximab can affect the quality of life temporarily; with long term treatment, severity of skin toxicity may decrease.

Drug interactions

Potentially hazardous interactions with other drugs
Avoid with live vaccines.

Metabolism

Several pathways have been described that may contribute to the metabolism of antibodies. All of these pathways involve the biodegradation of the antibody to smaller molecules, i.e. small peptides or amino acids.

References

[1] W Bou-Assaly, S Mukherji. “Cetuximab (erbitux).” American Journal of Neuroradiology 31 4 (2010): 626–7.

Cetuximab Preparation Products And Raw materials

Raw materials

Preparation Products

Global( 162)Suppliers
Supplier Tel Email Country ProdList Advantage
Shanghai Minbiotech Co., Ltd.
+8617315815539 sales@minbiotech.com CHINA 129 58
Henan Tianfu Chemical Co.,Ltd.
+86-0371-55170693 +86-19937530512 info@tianfuchem.com China 21689 55
Hubei xin bonus chemical co. LTD
86-13657291602 linda@hubeijusheng.com CHINA 22968 58
BOC Sciences
+1-631-485-4226 inquiry@bocsci.com United States 19553 58
TopScience Biochemical
00852-68527855 info@itopbiochem.com China Hong Kong 902 58
career henan chemical co
+86-0371-86658258 15093356674; factory@coreychem.com China 29826 58
Shaanxi Dideu Medichem Co. Ltd
+86-29-87569266 15319487004 1015@dideu.com China 2263 58
Hubei Ipure Biology Co., Ltd
+8613367258412 ada@ipurechemical.com China 10326 58
HONG KONG IPURE BIOLOGY CO.,LIMITED
86 18062405514 18062405514 ada@ipurechemical.com CHINA 3465 58
Dideu Industries Group Limited
+86-29-89586680 +86-15129568250 1026@dideu.com China 28302 58

Related articles

View Lastest Price from Cetuximab manufacturers

Image Update time Product Price Min. Order Purity Supply Ability Manufacturer
CETUXIMAB USP/EP/BP pictures 2021-07-03 CETUXIMAB USP/EP/BP
205923-56-4
US $1.10 / g 1g 99.9% 100 Tons Min Dideu Industries Group Limited
Cetuximab pictures 2020-05-03 Cetuximab
205923-56-4
US $0.00-0.00 / Kg 1KG 99.0% 800 ton Shaanxi Dideu Medichem Co. Ltd
CETUXIMAB pictures 2020-03-06 CETUXIMAB
205923-56-4
US $1.00 / KG 1KG 99% 200kgs Career Henan Chemical Co
  • Cetuximab pictures
  • Cetuximab
    205923-56-4
  • US $0.00-0.00 / Kg
  • 99.0%
  • Shaanxi Dideu Medichem Co. Ltd
  • CETUXIMAB pictures
  • CETUXIMAB
    205923-56-4
  • US $1.00 / KG
  • 99%
  • Career Henan Chemical Co
CETUXIMAB Hsdb 7454 Immunoglobulin G1, anti-(human epidermal growth factor receptor) (human-mouse monoclonal C225 gamma1-chain), disulfide with human-mouse monoclonal C225 kappa-chain, dimer Unii-pqx0D8J21j CetuxiMab(C225) IMC 225 Cetuximab - Buffer solution Cetuximab (anti-EGFR) CETUXIMAB USP/EP/BP 6-Diaminoheptanedioic acid EGFR antibody Research Grade Cetuximab(DHB86902) ImmunoglobulinG1, anti-(human epidermal growth factor receptor) (human-mouse monoclonal C225 g1-chain),disulfide with human-mouse monoclonal C225 k-chain, dimer 205923-56-4 C6484H10042N1732O2023S36